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Abstract
Introduction—Fish oil has been shown to reduce serum triglyceride (TG) concentrations. In HIV-
infected patients on antiretroviral therapy, high TG concentrations likely contribute to increased risk
of cardiovascular disease. AIDS Clinical Trials Group A5186 examined the safety and efficacy of
fish oil plus fenofibrate in subjects not achieving serum TG levels ≤200 mg/dL with either agent
alone.
Methods—One hundred subjects on highly active antiretroviral therapy with serum TG
concentrations ≥400 mg/dL and low-density lipoprotein cholesterol ≤160 mg/dL were randomized
to 3 g of fish oil twice daily or 160 mg of fenofibrate daily for 8 weeks. Subjects with a fasting TG
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level >200 mg/dL at week 8 received a combination of fish oil and fenofibrate in the same doses
from week 10 to week 18.
Results—Median baseline TG was 662 mg/dL in the fish oil group and 694 mg/dL in the fenofibrate
group (P = not significant). Fish oil reduced TG levels by a median of 283 mg/dL (46%), fenofibrate
reduced them by 367 mg/dL (58%), and combination therapy reduced them by 65.5%. Combination
therapy achieved TG levels of ≤200 mg/dL in 22.7% subjects. Fish oil had no measurable effect on
immunologic parameters or the pharmacokinetics of lopinavir.
Conclusions—Fish oil was safe when administered alone or combined with fenofibrate and
significantly reduced TG levels in HIV-infected subjects with hypertriglyceridemia.
Keywords
fenofibrate; fish oil; hypertriglyceridemia; low-density lipoprotein cholesterol; omega-3 fatty acids
Before the introduction of highly active antiretroviral therapy (HAART), HIV-infected persons
were noted to have elevated triglyceride (TG) levels with low total cholesterol and low high-
density lipoprotein cholesterol (HDL-C), presumably attributable to a persistent inflammatory
state. Furthermore, elevation of serum lipids is a frequent and serious complication associated
with the use of HAART.1-4 The most common lipid elevation observed is with the serum TG
level.5 Although ritonavir is the antiretroviral drug (ARV) most commonly associated with
this lipid change, other ARVs have also been associated with serum TG perturbations.6-8
There is mounting evidence that the observed metabolic syndrome characterized by elevated
TGs, low HDL-C, glucose intolerance, and body fat changes may accelerate the development
of atherosclerosis, leading to higher rates of cerebrovascular and coronary heart disease (CHD).
9,10 HIV-infected patients with HAART-induced hypertriglyceridemia have been observed to
have atherogenic dyslipidemia. Although there is not universal consensus,
hypertriglyceridemia is increasingly being recognized as an independent risk factor in the
development of CHD and is a secondary target for intervention in the most recent National
Cholesterol Education Project (NCEP) Adult Treatment Panel III guidelines.11-14 In addition
to increased CHD risks, high serum TG is associated with the development of pancreatitis.
Thus, the identification of effective therapy for drug-induced hypertriglyceridemia is an
important clinical concern. Presently, the recommended approaches to the treatment of serum
hypertriglyceridemia consist of diet, exercise, and the use of drugs like fibrates or niacin.15
Neither diet nor exercise is consistently effective because of the difficulty in adhering to these
lifestyle changes. Pharmacotherapy is somewhat effective, but in a large clinical trial in HIV-
infected subjects with lipid abnormalities, fenofibrate alone reduced serum TG level to <200
mg/dL (the NCEP Treatment Panel III guidelines’ suggested target level) in only 48% of the
subjects, with a median baseline serum TG level of 336 mg/dL.16
Fish oil has been shown to reduce serum TGs in disparate populations, including those with
congenital hypertriglyceridemia and drug-induced hypertriglyceridemia.17-19 Two trials
evaluating lower doses of fish oil than we used decreased the serum TG concentration by 25%
to 30% in HIV-infected individuals on ARVs.20,21 These studies were not designed to reduce
serum TG to ≤200 mg/dL, however. Fish oil is an attractive compound because of its described
effect in reducing atherogenic cardiovascular disease risk by means of a combination of anti-
inflammatory and antiplatelet effects.22 Epidemiologic studies have suggested that a diet rich
in omega-3 fatty acids is associated with a low incidence of CHD.23 In addition, the American
Heart Association’s dietary guidelines have recommended that healthy adults eat at least 2
servings of fish per week and that people who have elevated TGs need 2 to 4 g of
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) per day as a dietary
supplement.
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AIDS Clinical Trials Group (ACTG) A5186 was designed to test the hypothesis that we could
reach a TG goal <200 mg/dL in a significant proportion of subjects using fenofibrate plus fish
oil in those failing either agent alone. At the time this study was designed, these agents had not
been used in combination in this population. Further, we proposed using fish oil containing
higher doses of EPA and DHA than previously studied in persons with HIV. Thus, the study
was designed as a phase 2 study that, if successful, would merit a larger randomized controlled
trial. The primary objectives of ACTG A5186 were (1) to evaluate whether the combination
of fish oil supplement and fenofibrate would decrease fasting serum TGs to ≤200 mg/dL in
subjects not responding to either agent alone and (2) to evaluate the safety and tolerability of
fish oil supplement alone and in combination with fenofibrate in an HIV-infected population
with elevated fasting serum TGs.
The secondary objectives were (1) to evaluate the change in serum TG and low-density
lipoprotein cholesterol (LDL-C) with the combination of fish oil supplement and fenofibrate
and with each agent alone, (2) to describe the effect of fish oil supplement on lymphocyte
proliferative responses to Candida and cytomegalovirus (CMV) antigens, (3) to describe the
effect of fish oil supplement on C-reactive protein (CRP) concentrations, and (4) to describe




ACTG A5186 was a phase 2, randomized, open-label, multisite trial. Therapeutic response was
defined as achieving a fasting serum TG concentration ≤200 mg/dL. Eligible subjects entered
step 1 of ACTG A5186 and were randomized 1:1 into 1 of 2 treatment arms. Subjects in arm
A received 3 g of fish oil supplement twice a day, to be taken with meals (Advanced Nutritional
Technology, Dublin, CA; each gram of fish oil contains 500 mg of EPA, 310 mg of DHA, 190
mg of other omega-3 fatty acid, and 20 IU of d-alpha tocopherol). Subjects in arm B received
160 mg of fenofibrate once daily (Abbott Laboratories, Abbott Park, IL). Subjects were
evaluated for response to treatment at week 8. At week 10, the subjects who had not responded
were registered to step 2 and began combined therapy with fenofibrate and fish oil at the same
doses through week 18. Subjects who had responded to their step 1 treatment (fasting serum
TG ≤200 mg/dL) remained on their original single-agent therapy through week 18. All subjects
returned for a follow-up safety visit at week 22. The primary goal of the study was to determine
the proportion of subjects who responded to the combination of fish oil and fenofibrate when
there was no response to monotherapy. The primary endpoint was response (TG ≤200 mg/dL)
on step 2, with no statistical analysis comparing the step 2 response rate with the step 1
monotherapy response rate.
Inclusion and Exclusion Criteria
Subjects were at least 18 years of age with documented HIV infection who had been taking
HAART for at least 3 months before study entry and stable HAART for at least 4 weeks before
study entry. Serum lipid eligibility criteria included fasting serum TGs ≥400 mg/dL and LDL-
C ≤160 mg/dL by ultracentrifugation within 28 days before study entry. Fasting was defined
as no food or beverage (other than water) for 8 to 12 hours before blood draw. Subjects had to
be willing to remain on their current HAART regimen for the study duration, to have adhered
to a lipid-lowering diet and exercise program for at least 28 days before screening, and to be
willing to continue both for the study duration. All female subjects of reproductive potential
had to have a negative pregnancy test result at screening and again at study entry. Male subjects
on testosterone replacement therapy had to have been on stable therapy for at least 3 months
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before study entry and to remain on therapy for the study duration. A Karnofsky Performance
Scale score ≥70 was required within 28 days before study entry.
Exclusion criteria for step 1 included fasting glucose >126 mg/dL, platelet count <50,000
mm3, international normalized ration (INR) >1.5, absolute neutrophil count <750 mm3,
hemoglobin <9.1 g/dL for men and <8.9 g/dL for women, serum creatinine >1.5 times the
upper limit of normal (ULN), total bilirubin >2.5 times the ULN, alanine aminotransferase
(ALT) or aspartate aminotransferase (AST) >3 times the ULN, plasma HIV RNA level >10,000
copies/mL, documented CHD, congestive heart failure, uncontrolled hypertension, active
bleeding disorder, active peptic ulcer disease, diabetes mellitus requiring pharmacologic
therapy, untreated hypothyroidism, gallbladder disease, use of systemic cancer chemotherapy,
pregnancy, or breast-feeding. Subjects could not have received any lipid-lowering agent,
hormonal therapy except replacement testosterone, systemic corticosteroids, immune
modulators, anticoagulants, or investigational antiretroviral drugs within 28 days before study
entry. Subjects with allergy to study drugs, any active drug or alcohol dependence, mental
incapacity, acute illness, or active AIDS-defining infection within 28 days before study entry
that would have interfered with study participation were excluded. Exclusion criteria for step
2 included a week 8 INR >1.5.
Evaluations
A fasting lipid panel was obtained at screening and at weeks 4, 8, and 18 (plus week 14 for
step 2 subjects). In step 1, blood samples were collected from subjects in arm A at entry and
week 8 for lymphocyte proliferation assays (LPAs) to evaluate the immunologic effect of fish
oil. LPA samples were also collected in step 2 at weeks 10 and 18 from subjects who were
formerly in arm B. For subjects who were on a PI that was taken twice a day, plasma samples
were collected in arm A at entry and weeks 2 and 8 for trough PI concentrations. In step 2,
plasma samples for PI trough concentrations were collected at weeks 10, 12, and 18 from
subjects who were on a PI that was taken twice a day and who had been in arm B during step
1. Clinical and laboratory evaluations were assessed throughout the study. Adherence
evaluations using the standardized 4-day recall questionnaire were administered during the
study visits. In addition, all subjects had samples collected for measurement of serum high-
sensitivity (hs) CRP concentrations at baseline and weeks 8 and 18. Subjects were not allowed
to take any additional lipid-lowering therapies or over-the-counter lipid-lowering products
during the conduct of the study.
Laboratory Analysis
Lipid Levels—Total cholesterol, TG, and HDL-C values24 were determined by standard
techniques on a Roche Hitachi 917 (Roche Diagnostics, Basel, Switzerland, and Hitachi Ltd.,
Tokyo, Japan), and lipoprotein fractionation was determined by ultracentrifugation on a Quest
Diagnostics ultracentrifuge (Nicholls Institute, San Juan Capistrano, CA). LDL-C from
ultracentrifugation was determined after ultracentrifugation using a TL120 tabletop
ultracentrifuge (Beckman Coulter, Inc., Fullerton, CA). HDL-C and LDL-C were isolated
together by spinning them into a low-salt solution (0.9% NaCl). HDL-C alone was obtained
by centrifugation into a high-salt solution (16.7% NaCl). LDL-C was calculated by subtracting
the HDL-C (16.7% bottom) from the LDL-C plus HDL-C (0.9% bottom).
Lymphocyte Proliferation Assays—Peripheral blood specimens were shipped overnight
to a single laboratory, where peripheral blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque density centrifugation. Lymphocyte proliferation was assessed in a standard
6-day 3H-thymidine incorporation assay according to the consensus protocol of the ACTG
(available at:
http://aactg.s-3.com/pub/download/labmanual/29-ALM-Lymphocyte-Proliferation-
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Assay.pdf) to antigens of Candida albicans (10 μg/mL; Greer Laboratories, Lenoir, NC) and
CMV (1:1000; Bio Whittaker, Rockland, ME), the control CMV antigen (1:4000; Bio
Whittaker), and the mitogen phytohemagglutinin (PHA; 5 μg/mL; Sigma, St. Louis,
MO). 3H-thymidine incorporation was determined, and the stimulation index (SI) was
calculated by dividing the median counts per minute (cpm) of the antigen-containing wells by
the median cpm of 8 control wells into which no antigens had been placed or the CMV antigen
control. If this ratio was <1, the SI was defined as equal to 1.
Plasma PI Concentrations—Plasma concentrations of PIs were analyzed at the University
of Alabama at Birmingham ACTG Pharmacology Core Laboratory using a modified version
of a previously validated high-performance liquid chromatography (HPLC)-ultraviolet (UV)
method.25
Statistical Considerations
A priori, it was anticipated that 25% of subjects would respond to step 2 therapy. If the addition
of the second agent led to an incremental response rate of <10%, however, we determined that
the combination would not be appropriate for further clinical study. We estimated that 55
subjects would be required to advance to step 2 combination therapy to detect a difference of
15% (25% vs. 10%) in the step 2 response rate, along with 90% power and a 1-sided type I
error of 5%. We further estimated that an overall sample size of 100 subjects would be needed,
assuming a step 1 response rate of 35% and an overall dropout rate of 15%.
The Fisher exact test was used to detect between-group differences in categoric outcomes. The
Wilcoxon signed rank test was used to test within-group differences in continuous outcomes,
and the Wilcoxon rank sum test was used to test between-group differences in continuous
outcomes. Spearman rank coefficients were used to detect correlation between continuous
endpoints and baseline variables.
A fasting lipid panel was not obtained at week 10 (initiation of combination therapy); thus, all
step 2 lipid changes are calculated using week 8 and 18 data.
Approval, Support, and Conduct of the Study
The institutional review boards of the participating institutions approved the study, and each
study subject gave written informed consent. The study was approved by the scientific
committees of the ACTG and the National Institute of Allergy and Infectious Diseases
(NIAID), Division of AIDS.
RESULTS
Baseline Characteristics
One hundred subjects were randomized to the 2 arms of the study (arm A, fish oil = 50; arm
B, fenofibrate = 50). Baseline characteristics are outlined on Table 1. There were no baseline
differences in the 2 arms except that more subjects receiving a nonnucleoside reverse
transcriptase inhibitor (NNRTI)-based regimen were randomized to the fish oil arm of the
study. The baseline median CD4 count was 457 cells/μL, and 94% of subjects had an HIV
RNA level <200 copies/mL. The screening median fasting TGs were 668 mg/dL in arm A and
667 mg/dL in arm B. The screening median LDL-C, as measured by ultracentrifugation, was
85 mg/dL in arm A and 73 mg/dL in arm B. The median HDL-C was low, as previously
described for HIV-infected subjects.26 The median time between the screening lipid panel and
randomization was 20 days (21 days in the fish oil arm and 19 days in the fenofibrate arm).
The median difference from screening to entry TG level was −14 mg/dL (P = 0.71), which was
not significantly different from 0.
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The overall tolerability of the medications was excellent. During step 1 in arm A (fish oil),
only 1 subject discontinued medication because of protocol-defined toxicity (grade 3 nausea
and vomiting). Three other subjects in arm A discontinued medication for reasons unrelated
to drug toxicity. In arm B (fenofibrate), 3 subjects prematurely discontinued study medication
for toxicity; 2 of these cases were thought to be drug related, including grade 4 lipase and new-
onset renal insufficiency with a glomerular filtration rate (GFR) <50 mL/min. One toxicity
event was deemed unrelated to study drug (grade 2 muscle weakness). Five other subjects
discontinued medication for reasons unrelated to drug toxicity. Seven of the 12 step 1
medication discontinuations occurred at or before week 8. Of the 91 subjects on treatment and
with a TG result at week 8, 75 met criteria to advance to step 2. Of these subjects, 70 continued
on study medications through week 18. Of the subjects who discontinued study drugs, 1 did
so secondary to the development of grade 3 lipase elevation, which was a protocol-defined
drug toxicity; 1 stopped because of the pill burden and a fishy taste; 1 stopped for severe
headache that was not drug related; and 2 stopped for nonadherence to medications.
Primary Analysis of Data
The primary goal of the study was to determine the proportion of subjects who responded to
the combination of fish oil and fenofibrate when there was no response to monotherapy (Tables
2, 3). We expected a response rate in step 1 of 35% to achieve a TG concentration <200 mg/
dL, but the observed response rate was much lower: only 4 (8.5%) of 47 subjects on fish oil
and 8 (16.7%) of 48 subjects on fenofibrate responded. Thus, more subjects advanced to
combination therapy, improving the overall statistical power of the study. There were 75
subjects who went onto combination therapy. The primary analysis was intention to treat (ITT),
in which subjects with missing week 18 TG levels were analyzed as nonresponders. Among
the step 2 subjects, we observed a response rate of 22.7% (17 of 75 subjects). The lower limit
of the 1-sided exact 95% confidence interval was 15%, demonstrating that the combination of
fish oil and fenofibrate was deemed clinically appropriate for further study in subjects who did
not respond to monotherapy. The response rate was not significantly different if fish oil was
started first (21.4% for arm A) or fenofibrate first (24.2% for arm B).
By week 8, fish oil reduced TGs by a median of 283 mg/dL and fenofibrate by a median of
367 mg/dL, a difference that did not achieve statistical significance. When the data are
expressed as percent decrease in TGs, however, fish oil reduced TGs a median of 46%
compared with 58% for fenofibrate (P = 0.039). The median percent decrease in TGs from
screening to week 18 for step 2 subjects was 65.5%.
The decrease in TG levels was accompanied by a significant increase in LDL-C during step 1
and step 2. This increase in LDL-C has been previously described with fish oil and fenofibrate.
27,28 During step 1, HDL-C increased slightly, but this increase was only statistically significant
for arm B (median increase in arm A was 1 mg/dL and in arm B was 4 mg/dL). Fasting lipid
values for step 1 and step 2 are detailed in Tables 2 and 3. There were no significant changes
in hs-CRP in either arm or with combination therapy compared with baseline (data not shown).
Fish oil administration had no effect on absolute CD4 cell count or CD4 cell percent. The
median absolute CD4 count of all subjects was 451 cells/μL. The median change in CD4 count
at end of step 1 was an increase of 19 cells/μL (19 cells/μL in the fish oil arm and 18 cells/μL
in the fenofibrate arm). An additional median increase of 9 cells/μL occurred during step 2 on
combination therapy. There was no effect of fish oil administration on the lymphocyte SI to
Candida or CMV antigens (data not shown).
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In terms of pharmacokinetic effect of fish oil as evaluated by changes in trough concentrations
of PIs, only fixed-dose lopinavir/ritonavir use was sufficient for analysis. There were 18
subjects who had lopinavir trough concentrations before and after fish oil initiation, with trough
data 9 to 15 hours after lopinavir/ritonavir dosing. The median time of sample collection after
lopinavir/ritonavir dosing was 11.85 hours before fish oil administration and 11.75 hours
during fish oil administration. The median trough concentrations of lopinavir before and after
fish oil administration were 6453 ng/mL (range: 389 to 9881 ng/mL) and 5881 ng/mL (range:
416 to 13,960 ng/mL), respectively, which were not significantly different, suggesting that fish
oil had no effect on the pharmacokinetics of lopinavir.
DISCUSSION
Hypertriglyceridemia has been recognized as an independent risk factor in the development of
CHD.11 The most recent NCEP guidelines suggest that a more aggressive approach to therapy
is warranted, although the exact goal concentration for this lipid is still unclear, because TGs,
even in the range of 150 mg/dL, have been found to promote CHD in population-based studies.
14,29 HIV-infected patients on HAART frequently have elevated TGs and low HDL-C, similar
to those levels found among persons with type 2 diabetes, which places them in the high-risk
category for CHD.30 In addition, HIV infection is associated with diminished vascular
endothelial function31 and elevated hs-CRP; thus, aggressive and effective lipid-lowering
therapy is likely to be beneficial in reducing the overall risk of CHD, because these patients
live longer.32
Fish oil has been used to treat hypertriglyceridemia for 2 decades. The first description was in
the early 1980s, and fish oil was found to reduce TG concentration by as much as 80% in
subjects with familial hypertriglyceridemia.17 These subjects are phenotypically similar to
subjects on HAART therapy in that they have extremely high very-low-density lipoprotein
(VLDL) TG levels, normal to low LDL-C, and low HDL-C. In these subjects, an increase in
LDL-C secondary to fish oil was described similar to what was observed in the present study.
The increase in LDL-C was much less prominent in subjects with low baseline TGs. The
effectiveness of fish oil in lowering TG levels has a clear dose response relation, as
demonstrated by Harris et al.33 In addition, fish oil has been shown to have efficacy in lowering
TGs in subjects with drug-induced (retinoids) hypertriglyceridemia.34
We demonstrated that fish oil and fenofibrate alone could produce significant decreases in TG
levels; however, few patients on either therapy achieved TG levels lower than the NCEP target
of ≤200 mg/dL. Of note, most of our subjects were male and these results may not be
generalizable to a female population, although we are unaware of any data that suggest a
difference based on gender. The combination of both agents was found to reduce TG levels
further and to increase the proportion of subjects with a TG level ≤200 mg/dL among those
not achieving this target during monotherapy. These results demonstrate the relative ability of
each agent and their combination to treat hypertriglyceridemia in HIV-infected persons. The
modest effect of monotherapy on absolute TG levels suggests that for HIV-infected patients
with extremely elevated TGs, dual therapy may be preferable.
Administration of fish oil has been shown to have a beneficial effect in lowering TGs in HIV-
infected subjects in 2 other trials. De Truchis et al20 used a dose of EPA plus DHA of 1.8 g/d
and demonstrated a median decrease of 25.5% in TGs. The median baseline TG was 410 mg/
dL in this group, which was lower than in our subjects. Wohl et al21 administered 2.9 g/d of
EPA plus DHA in HIV-infected subjects on HAART and demonstrated a mean decrease in
fasting TGs of 25% in subjects with a mean baseline TG of 461 mg/dL. In both studies and in
our study, the tolerability of fish oil was excellent. Our study used a higher dose of fish oil
(4.86 g/d of EPA plus DHA), our subjects started with higher baseline TGs (median of 662
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mg/dL) than in the other studies, and we demonstrated a 46% decrease in TGs. Thus, it seems,
as in non-HIV-infected subjects, that the dose of fish oil correlates with the extent of response.
The combination of fish oil and fenofibrate was well tolerated with minimal toxicity. Although
we did not evaluate LDL particle size, data from other studies suggest that the expected increase
in LDL-C is secondary to an increase in larger more buoyant LDL, which is not as atherogenic
as the dense small LDL-C.19,27,35-38 In addition, initial LDL-C levels for subjects in our study
were lower than those in the general population and only increased to levels that are considered
normal for most subjects. It is unclear if the increase in LDL secondary to fenofibrate and fish
oil is long term and what the clinical implications of this effect are. Standard of practice is to
lower TGs first when TG levels exceed 500 mg/dL; after TGs are <400 mg/dL, the LDL can
be calculated to determine if LDL-lowering therapy is indicated.13,24 The small increase in
HDL-C was also expected and may partially counteract the effect on LDL-C.
Fish oil has been previously shown to be immunosuppressive by altering cytokine production
in PBMCs, reducing the percentage of helper T cells, and decreasing the mitogenic response
to concanavalin A.39 In contrast to what has been previously reported in healthy volunteers,
we did not observe any change in CD4 cell percent or absolute CD4 cell count in subjects
taking fish oil; in addition, the LPA responses to CMV and Candida antigens were not altered
by the fish oil supplement. Thus, this dose of fish oil seems to be immunologically safe.
Aside from evaluating the immunologic parameters, it was important to demonstrate that fish
oil administration had no adverse pharmacokinetic effect on boosted lopinavir—a PI in the
ARV class most closely associated with elevated TGs. Fish oil did not alter the trough
concentration of lopinavir, suggesting that fish oil would not be expected to modulate the
antiviral efficacy of ritonavir-boosted PIs.
In summary, we have demonstrated that fish oil at the EPA plus DHA dose of 4.86 g/d is
effective in combination with fenofibrate in lowering TGs in HIV-infected subjects with
hypertriglyceridemia on HAARTwho fail to respond to single-drug lipid-lowering therapy.
Most subjects failed to achieve the goal TG concentration of ≤200 mg/dL when treated with
fenofibrate or fish oil alone. When fish oil was combined with fenofibrate, however, a further
reduction in TGs was obtained without any safety concerns. HIV-associated dyslipidemia
remains a difficult condition to treat, and our trial further demonstrates the need for evaluation
of combination therapies or strategies to manage this comorbidity. Whether higher doses of
omega-3 fatty acids would result in a more effective antilipid effect should be studied; however,
immunologic monitoring should also be assessed.
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TABLE 1






No. subjects 50 50
Age (y) 43.5 (26 to 61) 43 (23 to 58)
Gender 90% male 96% male
Ethnicity 58% white 56% white
16% black 12% black
26% Hispanic 30% Hispanic
CD4 count (cells/μL) 429.5 (114 to 1264) 528.5 (109 to 1111)
HIV RNA level
 (copies/mL) <50 (<50 to 1483) <50 (<50 to 4210)
Screening serum lipids
 TG (mg/dL) 668 (402 to 2980) 667 (401 to 1922)
 LDL-C (mg/dL) 85 (31 to 152) 73 (30 to 160)
 HDL-C (mg/dL) 31 (21 to 43) 30 (21 to 42)
 TC (mg/dL) 243.5 (147 to 457) 240.5 (158 to 447)






18 (26) 21 (32)
 Subjects on EFV
  (on NVP) 29 (4) 20 (0)*
 Subjects on d4T 6 9
 Subjects on TDF 21 14
All values for age, CD4 cell count, HIV RNA level, and serum lipids are medians and ranges.
d4T indicates stavudine; EFV, efavirenz; NVP, nevirapine; TDF, tenofovir disoproxil fumarate.
*
P < 0.05, proportion on EFV or NVP, treatment A versus treatment B.
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